Skip to content
Telehealth Graded

Search Telehealth Graded

Use arrow keys or Tab to browse. Enter opens a result. Escape closes search.

Enter a name or topic to search.

State guide

Oregon Health Plan and GLP-1s

Published by Telehealth Graded · Updated

The takeaway

The Oregon Health Plan publishes a drug-by-drug table of covered uses and says drugs prescribed only for weight management are not covered.

Reading the state documents

Oregon organizes coverage around what the evidence supports rather than around what a drug is labeled for, and it publishes the resulting table. Liraglutide qualifies only for liver disease. Semaglutide qualifies for cardiovascular disease or liver disease. Tirzepatide qualifies for sleep apnea. Weight management alone qualifies for nothing — except that children keep a case-by-case review.

2
documents cited
6
sourced facts
2
primary sources

What changed, and what the document says

  1. The note above the evidence table

    Not covered

    Oregon states the rule as a heading over the table rather than burying it in a criteria step, so it governs everything below.

    “Note: Drugs prescribed for only weight management (overweight or obesity) are NOT currently covered”

    Oregon Drug Use Review / Pharmacy & Therapeutics Committee, Oregon Health Authority Health Systems Division — Review: 2/26 (SF); 4/25 (KS); 8/24 (SS/SF); 6/24 (KS) · Implementation: 3/1/26; 5/12/25; 9/1/24; 7/1/24

  2. A table of what the evidence supports

    Context

    The organizing idea is unusual: the list is of indications backed by evidence, not of drugs approved by a regulator.

    “Table 3. Evidence-Supported Indications”

    Oregon Drug Use Review / Pharmacy & Therapeutics Committee, Oregon Health Authority Health Systems Division — Review: 2/26 (SF); 4/25 (KS); 8/24 (SS/SF); 6/24 (KS) · Implementation: 3/1/26; 5/12/25; 9/1/24; 7/1/24

  3. Children keep a case-by-case route

    Covered

    The children's benefit is named as a goal of the policy itself, which is a different posture from an adult-only refusal.

    “Allow case-by-case review for members covered under the EPSDT program.”

    Oregon Drug Use Review / Pharmacy & Therapeutics Committee, Oregon Health Authority Health Systems Division — Review: 2/26 (SF); 4/25 (KS); 8/24 (SS/SF); 6/24 (KS) · Implementation: 3/1/26; 5/12/25; 9/1/24; 7/1/24

  4. Tirzepatide's one indication

    Conditions apply

    The evidence table gives each drug its own row. Tirzepatide gets a single line, and it is about breathing.

    “Moderate to severe obstructive sleep apnea (OSA) in adults with obesity”

    Oregon Drug Use Review / Pharmacy & Therapeutics Committee, Oregon Health Authority Health Systems Division — Review: 2/26 (SF); 4/25 (KS); 8/24 (SS/SF); 6/24 (KS) · Implementation: 3/1/26; 5/12/25; 9/1/24; 7/1/24

  5. The committee changed it in February

    Covered

    Oregon's committee voted to drop a step-therapy requirement, which makes the liver-disease route shorter for people without diabetes.

    “Recommendations: Remove Ozempic step through for Wegovy for patients who do not have diabetes”

    Drug Use Research & Management Program, Oregon Health Authority Health Systems Division — Thursday, February 5th, 2026

  6. It went through the committee as an agenda item

    Context

    The change was presented, taken to public comment and voted, rather than issued as a bulletin.

    “Motion to approve, 2nd, all in favor”

    Drug Use Research & Management Program, Oregon Health Authority Health Systems Division — Thursday, February 5th, 2026

Telehealth in Oregon

Some providers pay us a commission when you sign up through our links, at no extra cost to you.

Which of these companies serve Oregon?

Of the 387 companies we grade, 34 publish a list of the states they are licensed in. We checked 251 more and found no such list on any page we read; 102 we have not checked either way.

21 of those lists name Oregon: Gala Health, Care Bare Rx, Vita Bella, TelePeptide, Levity, Wisp, WePeptideRx, Ways2Well, TeleClinic, Tyde Wellness, Willow, VevaRx, Trimi, Enhance MD, HumeCare+, Rx.com, Mojoon, Peak Wellness, Sprout Health, Allara Health, and MEDvidi. That is a licensure claim each company makes about itself, not something we checked with a state board.

A published list is a starting point, not a guarantee. If availability decides your choice, ask before you pay and get the answer in writing.

Coverage decides what you pay before cash does. See how state Medicaid programs cover GLP-1s and what a prior-authorization denial turns on.

Sources

Source dates below are the dates printed on the documents.

  • Weight Management Drugs — prior authorization criteria — Oregon Drug Use Review / Pharmacy & Therapeutics Committee, Oregon Health Authority Health Systems Division. The two histories the footer prints, labeled there as P and T / DUR Review and Implementation; the document prints no single effective date: Review: 2/26 (SF); 4/25 (KS); 8/24 (SS/SF); 6/24 (KS) · Implementation: 3/1/26; 5/12/25; 9/1/24; 7/1/24.
  • Oregon Drug Use Review / Pharmacy & Therapeutics Committee — meeting minutes — Drug Use Research & Management Program, Oregon Health Authority Health Systems Division. Meeting date printed under the committee name on page 1: Thursday, February 5th, 2026.

Nothing on this page is medical advice, and nobody here is a clinician. Coverage rules change; check the linked document before you rely on it.

Browse 50 other state guides